Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Isagani Chico"'
Autor:
Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha Dubbewar, Laura Vidal, Isagani Chico, Eric Severson, Luigi Lorini, Sunil Badve, Paolo Bossi
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Recent strides in understanding the molecular underpinnings of head and neck cancers have sparked considerable interest in identifying precise biomarkers that can enhance prognostication and enable personalized treatment strategies. Immunotherapy has
Externí odkaz:
https://doaj.org/article/402cb59d0e0442be82309e8f45d3d0e6
Autor:
Arun K. Mankan, Abhishek Shankar, Sewanti Limaye, B.S. Ajaikumar, Prajakta Nachane, Navneet Singh, Shekhar Dawkhar, Ullas Batra, Amol Bhosekar, Sandip Ganguly, Pramod Gawli, Khokan Debnath, Vivek Padalalu, Prasanth Reddy, Shanthi Sundaramoorthy, K.K. Naveen, Shailesh Bondarde, Praveen Kumar, Sanish Davis, Shakti H. Ramkissoon, Raju Titus Chacko, Laura Vidal, Isagani Chico, Andrew Hegedus, Sudeep Gupta, Kamal S. Saini
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
Executing global clinical trials for cancer is a long, expensive, and complex undertaking. While selecting countries global studies, sponsors must consider several aspects including patient pool, quality of trained investigators, competing trials, av
Externí odkaz:
https://doaj.org/article/99f91b58bcd5454dae524c413746eb99
Autor:
Idoko Salifu, Navneet Singh, Maria Berraondo, Jordi Remon, Stephanie Salifu, Eric Severson, Angela Quintana, Sandra Peiró, Shakti Ramkissoon, Laura Vidal, Isagani Chico, Kamal S. Saini
Publikováno v:
Cancer Treatment and Research Communications, Vol 36, Iss , Pp 100713- (2023)
Introduction: Advanced non-small cell lung cancer (aNSCLC) is an incurable disease. The effort to develop treatments with more effective systemic agents continues. This has led to the FDA approval of one antibody–drug conjugate (ADC) and eight immu
Externí odkaz:
https://doaj.org/article/f0c24e34428c42d1adf674ebc5a07d72
Autor:
Begoña de las Heras, Adam Daehnke, Kamal S Saini, Melissa Harris, Kenneth Morrison, Ariel Aguilo, Isagani Chico, Laura Vidal, Robin Marcus
Publikováno v:
Digital Health, Vol 8 (2022)
As a result of the unprecedented challenges imposed by the COVID-19 pandemic on enrollment to cancer clinical trials, there has been an urgency to identify and incorporate new solutions to mitigate these difficulties. The concept of decentralized or
Externí odkaz:
https://doaj.org/article/f9f1ec8b4c0c4b8c9c92b6de326b3709
Autor:
neeraj kumar singh, Kamal S. Saini, Sangavai Chakkrapani, Eric Severson, Nahush Nagaraj, Shakti Ramkissoon, Isagani Chico, Ariel Aguilo, Rohini George, Laura Vidal, Smita Agrawal
Publikováno v:
Cancer Research. 83:923-923
Background: NCSLC is the leading cause of cancer deaths in the United States (USA). The 5-year survival rate is 22.9% (7% in those with metastases). Personalized therapies have shown promise but a better understanding of the genomic landscape of the
Autor:
Matteo Lambertini, Kamal S Saini, Monika Lamba Saini, Isagani Chico, Navneet Singh, Evandro de Azambuja, Laura Vidal, Diogo Martins-Branco, Marco Tagliamento, Giuseppe Curigliano, Kevin Punie
Publikováno v:
Oncology and Therapy
Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally. The pandemic has had a severe impact on oncology care and research. Patients with underlying cancer are more vulnerable to contracting COVID-19, and also have a more sev
Autor:
Roy Louis Maute, Amita Patnaik, Balaji Agoram, Yan V. Wang, Isagani Chico, Cathy Eng, Mark P. Chao, Philip A. Philip, Jens-Peter Volkmer, Peter J. O'Dwyer, J. Randolph Hecht, Tina M Ippolito, Chris H. Takimoto, Johanna C. Bendell, Benny Johnson, Nehal Lakhani, George A. Fisher, Adel Kardosh
Publikováno v:
Journal of Clinical Oncology. 38:114-114
114 Background: Magrolimab (M, Hu5F9-G4) is an antibody targeting CD47, a macrophage “don’t eat me” signal that demonstrates preclinical synergy with cetuximab (C) in refractory KRAS wild type (KRASwt) and KRAS mutant (KRASm) colorectal (CRC) t
Autor:
Peter L. Choyke, Beverly Meadows, Raymond C. Bergan, Barry R. Goldspiel, Clara C. Chen, Robert W. Robey, Tito Fojo, Thomas M. Smith, Isagani Chico, Susan Bakke, Susan E. Bates, Maria J. Merino, William D. Figg, Min H. Kang
Publikováno v:
Cancer. 92:1577-1590
BACKGROUND PSC 833 is a second-generation P-glycoprotein (Pgp) antagonist developed to reverse multidrug resistance (MDR). The authors conducted a Phase I study of orally administered PSC 833 in combination with vinblastine administered as a 5-day co
Autor:
Tito Fojo, Jame Abraham, Beverly Meadows, Peter L. Choyke, Seth M. Steinberg, Susan E. Bates, Isagani Chico, Ann Rutt, Raymond C. Bergan, Thomas W. Smith, Rob Robey, Min H. Kang, Barry R. Goldspiel, Susan Bakke, Maria J. Merino, William D. Figg
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(3)
PURPOSE: PSC 833 (valspodar) is a second-generation P-glycoprotein (Pgp) antagonist developed to reverse multidrug resistance. We conducted a phase I study of a 7-day oral administration of PSC 833 in combination with paclitaxel, administered as a 96
Autor:
Jens-Peter Volkmer, Chris H. Takimoto, Kathleen N. Moore, Roy Louis Maute, David Miller, Amita Patnaik, Matt Axt, Isagani Chico, Yan V. Wang, Balaji Agoram, John W. Moroney, Mark P. Chao, Andreas Schroeder, Nehal Lakhani, John B. Liao, Gini F. Fleming
Publikováno v:
Web of Science
18 Background: Magrolimab (M, Hu5F9-G4) is an antibody targeting CD47, a “don’t eat me” signal for macrophages that enhances ovarian cancer cell phagocytosis in preclinical models in combination with the PD-L1 inhibitor avelumab. CD47 blockade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::319379fa1d3200631e67fe4d80576a3c
https://publons.com/wos-op/publon/32026838/
https://publons.com/wos-op/publon/32026838/